← Back to headlines
Merck Finalizes $6B Terns Pharma Acquisition; Investors Question Premium
Merck has finalized its acquisition of Terns Pharmaceuticals for nearly $6 billion to boost its cancer drug pipeline, though analysts and investors are now questioning the premium paid for the deal.
25 Mar, 17:05 — 25 Mar, 17:05
Sources
Showing 1 of 1 sources
